Irvine, Calif.-based PathCentral has sold its diagnostic laboratory business to Ascend Clinical, a deal that will include the former company’s chief executive officer. Ascend Clinical, based in Redwood City, Calif., focuses primarily on laboratory testing for dialysis clinics and patients with end-stage renal disease. “Ascend brings a wealth of laboratory business knowledge to the table and our acquisition of PathCentral’s laboratory is a natural step for our company,” said Paul Beyer, Ascend Clinical’s chief executive officer. “This new addition to our service offering advances our vision of delivering broad spectrum clinical services.” Ascend Clinical said it would use the deal to help expand the tests it offers to clients. PathCentral said the divesting of its lab business would allow it to expand its anatomic pathology laboratory information system, or APLIS, which can connect providers across a Web-based platform. Through a deal struck by PathCentral in 2011 with a Chinese firm called KindStar GlobalGene Techonology, APLIS is widely used among providers in Southern China. PathCentral also plans to launch its online professional network in the first half of 2013. It is designed to connect pathologists around the world with subspecialty expert consultants. As part of the sale of the diagnostic lab […]
Irvine, Calif.-based PathCentral has sold its diagnostic laboratory business to Ascend Clinical, a deal that will include the former company’s chief executive officer.
Ascend Clinical, based in Redwood City, Calif., focuses primarily on laboratory testing for dialysis clinics and patients with end-stage renal disease.
“Ascend brings a wealth of laboratory business knowledge to the table and our acquisition of PathCentral’s laboratory is a natural step for our company,” said Paul Beyer, Ascend Clinical’s chief executive officer. “This new addition to our service offering advances our vision of delivering broad spectrum clinical services.”
Ascend Clinical said it would use the deal to help expand the tests it offers to clients.
PathCentral said the divesting of its lab business would allow it to expand its anatomic pathology laboratory information system, or APLIS, which can connect providers across a Web-based platform. Through a deal struck by PathCentral in 2011 with a Chinese firm called KindStar GlobalGene Techonology, APLIS is widely used among providers in Southern China.
PathCentral also plans to launch its online professional network in the first half of 2013. It is designed to connect pathologists around the world with subspecialty expert consultants.
As part of the sale of the diagnostic lab business, PathCentral CEO Matt Watson will transition to an executive role with Ascend in order to provide continuity for lab clients. Current PathCentral Chief Financial Officer Jaye Connolly will succeed Watson.
“As a focused technology company, we now can advance our long-term vision, which is to enable pathologists around the globe to tap and harness powerful cloud-based solutions, share their findings, and collaborate on an unprecedented level,” Connolly said.
